ClinicalTrials.gg
Status unknownNCT04205578NICE-MMDUpdated Dec 19, 2019

NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events

A Phase 3 interventional study of dl-3-n-butylphthalide (NBP) and Normal Saline 0.9% Infusion Solution in Moyamoya Disease, Ischemic Cerebral Infarction and Ischemic Stroke, sponsored by yuanli Zhao. Status unknown at 2 sites in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-12-19.

Sponsored by yuanli Zhao · Phase 3, Interventional, and Diagnostic

How we know

The sponsor has not verified this record recently (last verified Dec 2019), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Moyamoya Disease with a site in China — 17 open to participants now, 17 under way, none of them phase 3. Moyamoya Disease · China.

Planned enrollment
2nd of 17
450 · median 98
Started
2020
the only one that year
Phase 3
2 of 32
none open now
Registered
12th of 32
by date

Among the 32 studies in Moyamoya Disease with a site in China, this one is the 2nd largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2020, is one of 2 in phase 3, and was the 12th registered.

Moyamoya Disease

62 studies on the registry are indexed under Moyamoya Disease; 30 are open to participants now.

Browse Moyamoya Disease studies →

Open to participants now

17 of the 32 studies in Moyamoya Disease with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 22 Moyamoya Disease studies recruiting now, 9 (41%) set no upper age limit and 10 (45%) stop at 75 or younger; 9 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Moyamoya Disease with a site in China, or all of them as a file.
02

Study summary

An extracranial-to-intracranial (EC-IC) revascularization is the most widely used treatment to improve cerebral perfusion in patients with moyamoya disease (MMD), and it has been shown to reduce the risk of subsequent stroke and neurological deficit. However, perioperative changes in cerebral hemodynamics can induce fluctuations in cerebral perfusion that may lead to transient or irreversible neurological deficits. Our preliminary single-center study suggests that postoperative intravenous administration of dl-3-n-butylphthalide (NBP) may alleviate perioperative neurological deficits and improve the neurological outcomes after EC-IC revascularization for MMD. This is a multicenter, randomized, double-blind, single-controlled, add-on to standard of care study of NBP in patients with MMD of high risk for ischemic cerebrovascular events after EC-IC revascularization surgery.

Read the detailed description

This trial is a prospective, randomized, singe-blinded, placebo parallel controlled, multiple-center trial.

A total of approximately 450 patients (age between18 years and 60 years) with moyamoya disease after EC-IC revascularization will be enrolled. Patients fulfilling all of the inclusion criteria and none of the exclusion criteria will be randomized 1:1 into two groups after offering informed content: 1) one group will receive butylphthalide in 100 mL of normal saline twice daily since the day of surgery and continued for 14 postoperative days; 2) the other group will receive 100 mL of normal saline twice daily since the day of surgery and continued for 14 postoperative days.

The primary objective is to evaluate the rate and severity of ischemic cerebral event in MMD patients with butylphthalide after EC-IC bypass surgery. The study consists of four visits including the day of randomization(baseline), postoperative day 1 before the first injection, 14 days after surgery when the injection therapy is done, and 30 after suryery. Demographic information, symptoms and signs, laboratory test, neuro-imaging assessment, neurological function scale will be recorded during the program. The rate of stroke event, neurological deficit and severity of neurological deficits will be assessed by modified Rankin scale. The trial is anticipated to last from January 2020 to December 2022 with subjects recruited form two neurosurgical centers in Beijing, China.

03

Conditions studied

  • Moyamoya Disease
  • Ischemic Cerebral Infarction
  • Ischemic Stroke
  • Ischemic Cerebrovascular Accident
  • Transient Ischemic Attack

Keywords

  • Dl-3-n-butylphthalide
  • Revascularization surgery
  • Extracranial-to-intracranial revascularization
  • Direct bypass surgery
  • Combined bypass surgery
  • Indirect bypass surgery
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females aged ≥ 18 and ≤ 60 years.
  2. Women of (WOCBP) must have a negative urine HCG pregnancy test at Screening and be practicing a medically acceptable method of with an annual failure rate of less than 1% until the completion of the trial or 60 days after discontinuation of study treatment. Women are considered not childbearing if they are > 1 year or surgically sterile (ie, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy tubal ligation). If serum bHCG is the standard of care, then this value can be used to determine eligibility.
  3. A clinical diagnosis of moyamoya disease, including unilateral and bilateral disease.
  4. Previous clinical diagnosis of stroke or or undiagnosed infarction evidenced on screening CT or MRI
  5. Patients with moyamoya disease underwent extra cranial-to-intracranial (EC-IC) bypass surgery, including direct or indirect or combined EC-IC bypass surgery
  6. Capable of understanding the purpose and risk of the study and has signed, in writing, the ICF. If the subject is not capable of this at the time of enrollment, a legally authorized representative will provide written in accordance with all regulations.
  7. Ability to comply with study follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who are pregnant, lactating/breast-feeding, or plan to become pregnant within the next 3 months.
  2. severely disabled, as defined by a Modified Rankin Scale (mRS) score more than 3.
  3. History of intracranial hemorrhage.
  4. Postoperative intracranial hemorrhage on CT scan at 4 hours after surgery.
  5. Dementia or other progressive neurological disease.
  6. Known \< 6 months (for any reason).
  7. Known allergy or to celery.
  8. Received treatment with any other drug within 30 days before baseline, was previously treated with NBP, is currently taking celery seed extract, or is currently participating in another clinical study.
  9. Persons unable or unlikely to return for follow-up visits.
  10. Any other reasons that, in the opinion of the investigator, make the subject unsuitable for enrollment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
450 participants (estimated)

Study arms

  • Active comparator
    Butylphthalide (NBP)

    For patients without obvious intracranial hemorrhage on CT scan at 4 hours after surgery, 25 mg of NBP in 100 mL of normal saline was administered intravenously since the day of surgery and continued twice daily for 14 postoperative days.

    Drug: dl-3-n-butylphthalide (NBP)

  • Placebo comparator
    Normal saline

    For patients without obvious intracranial hemorrhage on CT scan at 4 hours after surgery, 100 mL of normal saline was administered intravenously since the day of surgery and continued twice daily for 14 postoperative days.

    Drug: Normal Saline 0.9% Infusion Solution

Interventions

  • DrugButylphthalideStudies of ButylphthalideButylphthalide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    25 mg of NBP in 100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.

  • DrugNormal Saline 0.9% Infusion Solution

    100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.

06

What researchers measure

Primary outcomes

  1. Perioperative ischemic stroke rate

    Perioperative cerebral stroke was defined as a symptomatic event of new cerebral infarction within 30 days after surgery and confirmed by CT or MRI. Symptoms included focal neurological deficit or headache lasting more than 24 hours.

    Time frame: within 30 days after surgery

  2. Perioperative death rate

    Rate of perioperative death of any cause within 30 days after surgery

    Time frame: within 30 days after surgery

  3. Rate of transient neurological deficit (TND)

    TND was defined as either any reversible neurological deficits observed objectively (e.g., hemiparesis, dysarthria) or any reversible neurological deficits recognized and reported subjectively (e.g., facial palsy), and without evidence of intracranial hemorrhage and cerebral infarction on images

    Time frame: within 30 days after surgery

Secondary outcomes

  1. modified Rankin Scale scores at 30 days after surgery

    The modified Rankin Scale scores were recorded at 1 month after surgery.

    Time frame: at 30 days after surgery

  2. The severity of transient neurological deficit

    The severity of TND was further categorized into four grades based on the clinical symptoms and duration6: Grade 0, none TND; Grade 1, symptoms resolved within 5 days; Grade 2, symptoms prolonged for 5 to 9 days; Grade 3; symptoms prolonged for 10 or more days. One grade worse was scored if there were hemiparesis and/or seizure.

    Time frame: within 30 days after surgery

  3. Postoperative intracranial hemorrhagic event

    New-onset intracranial hemorrhage within 30 days after surgery and confirmed by CT or MRI.

    Time frame: within 30 days after surgery

07

Study locations

2 sites
  • Beijing Tiantan Hospital, Capital Medical University
    Beijing, Beijing 100079, China
  • Peking University International Hospital
    Beijing, Beijing 102206, China
08

References and documents

Individual participant data

Plan to share: Yes — Study Protocol to be published in peer-reviewed journal

Supporting information: Study protocol

Time frame: Since the publication of study protocol

Access criteria: Available from the principle investigator upon reasonable request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2020; primary completion for Dec 2022, 35 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2019
First posted
Dec 19, 2019
StartEst.
Jan 2020
Primary completionEst.
Dec 31, 2022
CompletionEst.
Dec 31, 2022
Last update
Dec 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04205578
Lead sponsor
yuanli Zhao
Collaborators
Peking University International Hospital
Responsible party
yuanli Zhao (Professor, Department of Neurosurgery, Beijing Tiantan Hospital) — Sponsor-investigator
First posted
Dec 19, 2019
Start date
Jan 2020 (estimated)
Primary completion
Dec 31, 2022 (estimated)
Completion
Dec 31, 2022 (estimated)
Last update
Dec 19, 2019

Study contacts

Zongze Li, MD
Contact
lizongze@pkuih.edu.cn
86-13121226581
Li Ma, MD, PhD
Contact
marygl@hotmail.com
86-010-59978317
Yuanli Zhao, MD
study director · Beijing Tiantan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Butylphthalide

Start the discussion